Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels
| Autor: | Feng-Hua Xue, Shi-Chao Teng, Jing Zhu, Fang-Cheng Su, Shao-Xia Sun, Ming-Yu Shi, Hong-Yue Gu, Feng Yin, Li Jiang, Xi-Dong Li |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Statin Article Subject medicine.drug_class Atorvastatin lcsh:Medicine Pharmacology General Biochemistry Genetics and Molecular Biology Internal medicine Atrial Fibrillation medicine Odds Ratio Humans General Immunology and Microbiology biology business.industry C-reactive protein lcsh:R Case-control study Atrial fibrillation General Medicine Publication bias Odds ratio Middle Aged medicine.disease C-Reactive Protein Case-Control Studies Cardiology biology.protein Female business Publication Bias Cohort study medicine.drug Research Article |
| Zdroj: | BioMed Research International, Vol 2015 (2015) BioMed Research International |
| ISSN: | 2314-6133 |
| DOI: | 10.1155/2015/402481 |
| Popis: | We investigated whether serum hs-CRP levels predict the efficacy of atrial fibrillation (AF) treated with atorvastatin. Bibliographic databases were exhaustively searched for studies relevant to the research topic. Newcastle-Ottawa Scale (NOS) criteria, combined with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS), were applied for study quality assessment. Our meta-analysis identified seven cohort studies (2006~2013), providing information on the change in serum hs-CRP levels in AF patients receiving atorvastatin therapy. After atorvastatin treatment, hs-CRP level in AF patients decreased significantly (SMD = 1.02, 95% CI: 0.58–1.47,P<0.001). Subgroup analysis by country and hs-CRP detection methods suggested a negative relationship between atorvastatin treatment and hs-CRP levels among Chinese AF patients (SMD = 1.34, 95% CI: 1.00–1.69,P<0.001) and by using ELISA method (SMD = 1.11, 95% CI: 0.51–1.71,P<0.001), but not among Turkish population and using INA method (allP>0.05). Egger’s test showed no publication bias (P=0.450). hs-CRP was clearly lowered in AF patients treated with atorvastatin, which may be helpful in the choice of statin agents for AF treatment. However, longer follow-ups are necessary to assess the clinical value of lowering hs-CRP in the clinical setting of AF treatment outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|